A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Stopped Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

• DRUG: naquotinib mesilate
• DRUG: Erlotinib
• DRUG: Gefitinib

Sponsor

Astellas Pharma Global Development, Inc.